HC Wainwright & Co. assumes coverage of Autolus Therapeutics at Buy, sets price target at $10
HC Wainwright initiated coverage of Autolus Therapeutics with a Buy rating and $10 price target, implying 557.9% upside from $1.52 close on Oct 30.
How this was made

The 30-second read
Why it matters
The new coverage and price target could trigger short‑term buying, especially from retail and small‑cap focused funds.
Market read
Primary micro‑cap news; may affect AUTL and biotech sentiment but limited broader market impact.
What to watch
Potential regulatory setbacks or clinical trial delays could negate the upside.
Background
Autolus Therapeutics (NASDAQ:AUTL) is a clinical‑stage immunotherapy company focused on engineered T‑cell therapies.
Ticker impact
HC Wainwright initiates coverage of Autolus Therapeutics with a Buy rating and a $10 price target, implying a 558% upside from the recent close.
upward pressure as investors price in the new target
Coverage initiation and a large upside estimate are fresh, material signals for a micro‑cap biotech.
Market effects
May lift sentiment in the biotech sector as analysts seek undervalued targets.
Limited to US biotech investors; negligible broader market effect.
Low
Counterpoint
The $10 target may be overly optimistic given Autolus' early‑stage pipeline and valuation volatility.
Key entities
- analystHC Wainwright & Co.
Equity research firm that initiated coverage with a Buy rating.
- companyAutolus Therapeutics
Biotech firm developing T‑cell therapies, listed on NASDAQ.

